| 标题 |
专利、报告等 Update on the phase II study: to explore the efficacy and safety of luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma with MAPK pathway-activated
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | 寻找 2025 ESMO mini oral 661MO的PPT |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)